

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human FOLR3 in direct ELISAs and Western blots. In direct ELISAs, 10% cross-reactivity with recombinant human (rh) FOLR2 is observed and no cross-reactivity with rhFOLR4 is observed.
Source	Monoclonal Mouse IgG ₁ Clone # 553701
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Mouse myeloma cell line NS0-derived recombinant human FOLR3 long isoform Ala22-Ser245 Accession # NP_000795
Conjugate	Alexa Fluor 750 Excitation Wavelength: 749 nm Emission Wavelength: 775 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

Western Blot Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

Folate receptor 3 (FOLR3), also known as folate receptor γ, is a 32 kDa protein that binds folic acid and reduced folates. Dietary folates are required for many key metabolic processes including nucleotide and methionine synthesis, the interconversion of glycine and serine, and histidine breakdown (1). Mature FOLR3 is a glycosylated protein that contains an imperfect carboxy terminal GPI anchor sequence (2, 3). A fraction of FOLR3 is GPI-linked to the cell surface, but the majority is released as a secreted protein (2). Mature human FOLR3 shares 74% and 83% amino acid (aa) sequence identity with FOLR1 and FOLR2, respectively. Orthologs of human FOLR3 have not been described in mouse or rat. A genetic polymorphism generates a truncated isoform that lacks the carboxy terminal 139 aa (2, 4). FOLR3 is expressed by cells of the myelocyte and B lymphocyte lineage as well as by various carcinomas (2, 3). FOLR3 is more highly expressed in ovarian carcinomas than in breast carcinomas or mesotheliomas (5). Unlike other folate receptors, FOLR3 does not exhibit stereoselectivity in the binding of folates (3).

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.